Pharma Leader Series Top 26 Asthma & COPD Companies 2020-2030
The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 177-page report you will receive 100 charts– all unavailable elsewhere.
The 177-page report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Global Asthma & COPD Therapies Market forecasts from 2020-2030
- Profiles of the leading 26 asthma & COPD companies:
- Adamis Pharmaceuticals Corporation
- Aerocrine (Circassia)
- ALK-Abello A/S
- Amphastar Pharmaceuticals, Inc.
- AstraZeneca
- Boehringer Ingelheim
- Chiesi Farmaceutici
- Cipla
- Dimerix
- GlaxoSmithKline
- Innoviva
- Lallemand Pharma International
- Merck
- Mereo BioPharma Group plc
- MundiPharma
- Novartis
- Pulmatrix
- Respiratorius AB
- Roche
- Other companies
- The content of each profile differs, depending on the organization. In general, a profile gives the following information:
- An overview and analysis of the company
- A portfolio of the company’s marketed product and product pipeline
- Financial Information
- Revenue forecast from 2020-2030
- Recent developments
- Future Outlook
- This report discusses factors that drive and restrain the asthma and COPD market.
- Key questions answered by this report:
- How is the Asthma & COPD Companies market evolving?
- What is driving and restraining the Asthma & COPD Companies market?
- What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
- What will be the main driver for the overall market from 2019 to 2030?
- Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- Who are the leading players and what are their prospects over the forecast period?
- What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
- How will the industry evolve during the period between 2019 and 2030?
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1 Report Overview
- 1.1 Global Asthma & COPD Companies Market Overview
- 1.2 Global Asthma & COPD Companies Market Segmentation
- 1.3 Why You Should Read This Report
- 1.4 How This Report Delivers
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who Is This Report For?
- 1.7 Methodology
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2 Introduction to Asthma & COPD Therapies
- 2.1 COPD Overview
- 2.1.1 Chronic Obstructive Pulmonary Disease Medications
- 2.1.1.1 Bronchodilators
- 2.1.1.2 Glucocorticoids
- 2.2 Asthma Overview
- 2.2.1 Desirable inhaler characteristics for treating asthma
- 2.3 Asthma & COPD Respiratory Inhalers Overview
- 2.3.1 Nebulizers
- 2.3.2 Metered Dose Inhaler
- 2.3.3 Breath-Actuated Pressurised Metered-Dose Inhalers
- 2.3.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices
- 2.3.5 Dry powder inhalers (DPIs)
- 2.3.6 Soft Mist Inhalers
- 2.4 Asthma & COPD Therapies – Realising Their Potential, Market Drivers
- 2.4.1 Combination Therapies - Asthma & COPD Products
- 2.4.1.1 LAMA/LABA Combinations
- 2.4.1.2 LABA/LCS Combination
- 2.4.1.3 LABA+LAMA Vs. LABA+ICS Combinations
- 2.4.2 Triple Combination – Asthma & COPD Products
- 2.4.2.1.1 LAMA/LABA/ICS “Triple Combination Inhalers”
- 2.4.3 Opportunities in Telehealth
- 2.5 Market Restraints
- 2.6 Asthma & COPD Products: Trends and Developments
- 2.6.1 E-Technology in Asthma and COPD
- 3 Leading Asthma & COPD Companies: Overview, 2019
- 3.1 The Global Asthma & COPD Companies Market In 2019
- 3.2 Leading Companies in the Asthma & COPD Market, 2020
- 3.3 How Will Leading Companies’ Market Shares Change To 2030?
- 4 Leading Asthma & COPD Companies Worldwide, 2020
- 4.1 Astrazeneca – Company Overview & Analysis
- 4.1.1 Astrazeneca Marketed Asthma & COPD Products
- 4.1.1.1 Latest Developments Related to Key Marketed Products
- 4.1.1.1.1 Symbicort: Recent Developments
- 4.1.1.1.2 Bevespi Aerosphere: Recent Developments
- 4.1.1.1.3 Tudorza/ Eklira Genuair: Recent Developments
- 4.1.1.1.4 Duaklir: Recent Developments
- 4.1.1.1.5 Fasenra: Recent Developments
- 4.1.1.1.6 Other Recent Developments
- 4.1.2 Astrazeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.1.2.1 Latest Developments Related to Key Pipeline Products
- 4.1.2.1.1 Pt010/ Pt009/ Pt008/ Pt005: Pipeline Developments
- 4.1.2.1.2 Fasenra: Pipeline Developments
- 4.1.2.1.3 Tezepelumab: Pipeline Developments
- 4.1.2.1.4 Tralokinumab: Pipeline Developments
- 4.1.3 Astrazeneca -Asthma & COPD Market Forecast, 2019-2030
- 4.2 Glaxosmithkline – Company Overview & Analysis
- 4.2.1 Glaxosmithkline Marketed Asthma & COPD Products
- 4.2.1.1 Latest Developments Related to Key Marketed Products
- 4.2.1.1.1 Relvar/Breo Ellipta: Recent Developments
- 4.2.1.1.2 Anoro Ellipta: Recent Developments
- 4.2.1.1.3 Nucala: Recent Developments
- 4.2.1.1.4 Seretide/Advair: Recent Developments
- 4.2.1.1.5 Trelegy Ellipta: Recent Developments
- 4.2.1.1.6 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments
- 4.2.2 Glaxosmithkline, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.2.2.1 Latest Developments Related to Key Pipeline Products
- 4.2.2.1.1 Nucala: Recent Developments
- 4.2.3 Glaxosmithkline -Asthma & COPD Market Forecast, 2019-2030
- 4.3 Boehringer Ingelheim – Company Overview & Analysis
- 4.3.1 Boehringer Ingelheim Marketed Asthma & COPD Products
- 4.3.1.1 Latest Developments Related to Key Marketed Products
- 4.3.1.1.1 Spiriva Respimat: Recent Developments
- 4.3.1.1.1 Spiolto Respimat: Recent Developments
- 4.3.1.1.2 Ofev: Recent Developments
- 4.3.2 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.3.3 Boehringer Ingelheim -Asthma & COPD Market Forecast, 2019-2030
- 4.4 Teva – Company Overview & Analysis
- 4.4.1 Teva Marketed Asthma & COPD Products
- 4.4.1.1 Latest Developments Related to Key Marketed Products
- 4.4.1.1.1 Qvar: Recent Developments
- 4.4.1.1.2 Proair HFA: Recent Development
- 4.4.1.1.3 : Duoresp Spiromax: Recent Developments
- 4.4.1.1.4 Aerivio Spiromax: Recent Developments
- 4.4.1.1.5 Cinqair/Cinqaero: Recent Developments
- 4.4.1.1.6 Airduo Respiclick / Armonair Respiclick: Recent Development
- 4.4.2 Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.4.2.1 Latest Developments Related to Key Pipeline Products
- 4.4.2.1.1 Proair E-Respiclick: Recent Developments
- 4.4.3 Teva -Asthma & COPD Market Forecast, 2019-2030
- 4.5 Merck – Company Overview & Analysis
- 4.5.1 Merck Marketed Asthma & COPD Products
- 4.5.1.1 Latest Developments Related to Key Marketed Products
- 4.5.1.1.1 Dulera: Recent Development
- 4.5.2 Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.5.3 Merck -Asthma & COPD Market Forecast, 2019-2030
- 4.6 Roche – Company Overview & Analysis
- 4.6.1 Roche Marketed Asthma & COPD Products
- 4.6.1.1 Latest Developments Related to Key Marketed Products
- 4.6.1.1.1 Xolair: Recent Developments
- 4.6.2 Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.6.2.1 Latest Developments Related to Key Pipeline Products
- 4.6.2.1.1 Rg3637: Pipeline Developments
- 4.6.3 Roche -Asthma & COPD Market Forecast, 2019-2030
- 4.7 Novartis – Company Overview & Analysis
- 4.7.1 Novartis Marketed Asthma & COPD Products
- 4.7.1.1 Latest Developments Related to Key Marketed Products
- 4.7.1.1.1 Ultibro Breezhaler: Recent Developments
- 4.7.1.1.2 Xolair: Recent Developments
- 4.7.2 Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.7.2.1 Latest Developments Related to Key Pipeline Products
- 4.7.2.1.1 Qaw039: Pipeline Developments
- 4.7.2.1.2 Qbw251: Pipeline Developments
- 4.7.2.1.3 Qvm149: Pipeline Developments
- 4.7.2.1.4 Csj117: Pipeline Developments
- 4.7.2.1.5 Cjm112: Pipeline Developments
- 4.7.3 Novartis -Asthma & COPD Market Forecast, 2019-2030
- 4.8 Regeneron Pharmaceuticals (Sanofi)– Company Overview & Analysis
- 4.8.1 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.8.1.1 Latest Developments Related to Key Pipeline Products
- 4.8.1.1.1 Dupilimab/ Dupixent/Sar23189: Pipeline Developments
- 4.8.1.1.2 Sar440340: Pipeline Developments
- 4.8.2 Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2019-2030
- 4.9 Mundipharma – Company Overview & Analysis
- 4.9.1 Mundipharma Marketed Asthma & COPD Products
- 4.9.1.1 Latest Developments Related to Key Marketed Products
- 4.9.1.1.1 Flutiform (Fluticasone Propionate and Formoterol): Recent Developments
- 4.9.1.1.2 Company Related Developments
- 4.9.2 Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.9.2.1 Latest Developments Related to Key Pipeline Products
- 4.9.2.1.1 Flutiform K-Haler (Fluticasone Propionate and Formoterol): Recent Developments
- 4.10 Theravance Biopharma – Company Overview & Analysis
- 4.10.1 Theravance Biopharma Marketed Asthma & COPD Products
- 4.10.1.1 Latest Developments Related to Key Marketed Products
- 4.10.1.1.1 Trelegy Ellipta: Recent Developments
- 4.10.2 Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.10.2.1 Latest Developments Related to Key Pipeline Products
- 4.10.2.1.1 Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA): Recent Developments
- 4.10.2.2 Revefenacin (Td-4208): Recent Developments
- 4.11 Amphastar Pharmaceuticals – Company Overview & Analysis
- 4.11.1 Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.11.1.1 Latest Developments Related to Key Pipeline Products
- 4.11.1.1.1 Primatene Mist HFA: Recent Developments
- 4.11.1.1.2 Albuterol Dpi: Recent Developments
- 4.12 Cipla– Company Overview & Analysis
- 4.12.1 Cipla Marketed Asthma & COPD Products
- 4.12.1.1 Latest Developments Related to Key Marketed Products
- 4.12.1.1.1 Budesonide Inhalation Suspension: Pipeline Developments
- 4.12.1.1.2 Synchrobreathe: Pipeline Developments
- 4.12.1.2 Cipla Launch Plans for Respiratory Products
- 4.13 Sunovion Pharmaceuticals– Company Overview & Analysis
- 4.13.1 Sunovion Pharmaceuticals: Marketed Asthma & COPD Products
- 4.13.1.1 Latest Developments Related to Key Marketed Products
- 4.13.1.1.1 Sun-101: Recent Developments
- 4.13.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.13.3 Sunovion -Asthma & COPD Market Forecast, 2019-2030
- 4.14 Aerocrine (Circassia)– Company Overview & Analysis
- 4.14.1 Circassia Marketed Asthma & COPD Products
- 4.14.1.1 Latest Developments Related to Key Marketed Products
- 4.14.1.1.1 Niox: Recent Developments
- 4.14.1.1.2 Tudorza Pressair: Recent Developments
- 4.14.2 Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.14.2.1 Latest Developments Related to Key Pipeline Products
- 4.14.2.1.1 Duaklir Pressair Us: Pipeline Developments
- 4.14.3 Circassia -Asthma & COPD Market Forecast, 2019-2030
- 4.15 Vectura Group – Company Overview & Analysis
- 4.15.1 Vectura Group Marketed Asthma & COPD Products
- 4.15.1.1 Latest Developments Related to The Marketed Products
- 4.15.1.1.1 Flutiform (Mundipharma, Europe And Rest of World (Excl. North America)/Kyorin, Japan): Recent Developments
- 4.15.1.1.2 Ultibro Breezhaler, Seebri Breezhaler Utibron Neohaler Inhalation Powder and Seebri Neohaler (Novartis/Sunovion, US): Recent Developments
- 4.15.1.1.3 GSK Ellipta Products: Recent Developments
- 4.15.1.1.4 Airflusal Forspiro (Sandoz, Eu & Row): Recent Developments
- 4.15.1.1.5 Breelibtm (Bayer, Eu & Row Excluding Us): Recent Developments
- 4.15.2 Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.15.2.1 Latest Developments Related to The Pipeline Products
- 4.15.2.1.1 Vr647 (Paediatric Asthma Us): Recent Developments
- 4.15.2.1.2 Vr475 (Severe Adult Asthma Eu): Recent Developments
- 4.15.2.1.3 Vr315 (Hikma, Us): Recent Developments
- 4.15.2.1.4 Vr632 (Sandoz, Eu): Recent Developments
- 4.15.2.1.5 Vr410 (Pulmatrix, Us): Recent Developments
- 4.15.2.1.6 Qvm149 (Novartis: Europe & Row): Recent Developments
- 4.15.2.1.7 Key Outlook For 2018-2019
- 4.15.3 Vectura Group -Asthma & COPD Market Forecast, 2019-2030
- 4.16 Lallemand Pharma Ag– Company Overview & Analysis
- 4.16.1 Lallemand Pharma Ag Marketed Asthma & COPD Products
- 4.16.1.1 Latest Development Related to The Marketed Products
- 4.16.1.1.1 PMBL: Recent Developments
- 4.16.2 Lallemand Pharma Ag, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.16.3 Lallemand Pharma -Asthma & COPD Market Forecast, 2019-2030
- 4.17 Chiesi Farmaceutici S.P.A. – Company Overview & Analysis
- 4.17.1 Chiesi Farmaceutici S.P.A Marketed Asthma & COPD Products
- 4.17.1.1 Latest Developments Related to Key Marketed Products
- 4.17.1.1.1 Trimbow: Recent Developments
- 4.17.2 Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.17.2.1 Latest Developments Related to Key Pipeline Products
- 4.17.2.1.1 Bronchitol: Recent Development
- 4.17.2.1.2 CHF 6297: Recent Development
- 4.17.3 Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2019-2030
- 4.18 Pulmatrix: Company Overview & Analysis
- 4.18.1 Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.18.1.1 Latest Developments Related to Key Pipeline Products
- 4.18.1.1.1 Pur0200-Us: Recent Development
- 4.18.1.1.2 Pur1900: Recent Development
- 4.19 Verona Pharma Plc– Company Overview & Analysis
- 4.19.1 Verona Pharma Plc, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.19.1.1 Latest Development Related to The Pipeline Products
- 4.19.1.1.1 Rpl554: Recent Developments
- 4.19.2 Verona Pharma Plc -Asthma & COPD Market Forecast, 2019-2030
- 4.20 Alk-Abelló A/S– Company Overview & Analysis
- 4.20.1 Alk-Abelló A/S Marketed Asthma & COPD Products
- 4.20.2 Alk-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.20.2.1 Latest Developments Related to The Pipeline Products
- 4.20.2.1.1 Grazax: Recent Developments
- 4.20.3 Alk-Abelló A/S -Asthma & COPD Market Forecast, 2019-2030
- 4.21 Tff Pharmaceuticals, Inc.– Company Overview & Analysis
- 4.21.1 Tff Pharmaceuticals, Inc. Marketed Asthma & COPD Products
- 4.21.2 Tff Pharmaceuticals, Inc.: Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.21.2.1 Latest Developments Related to The Pipeline Products
- 4.21.2.1.1 Tff Triple Combination: Recent Developments
- 4.21.3 Tff Pharmaceuticals, Inc.-Asthma & COPD Market Forecast, 2019-2030
- 4.22 Respiratorius Ab – Company Overview & Analysis
- 4.22.1 Respiratorius Ab. Marketed Asthma & COPD Products
- 4.22.2 Respiratorius Ab: Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.22.2.1 Latest Developments Related to The Pipeline Products
- 4.22.2.1.1 Product: Recent Developments
- 4.22.3 Respiratorius Ab-Asthma & COPD Market Forecast, 2019-2030
- 4.23 Adamis Pharmaceuticals Corporation– Company Overview & Analysis
- 4.23.1 Adamis Pharmaceuticals Corporation. Marketed Asthma & COPD Products
- 4.23.2 Adamis Pharmaceuticals Corporation: Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.23.2.1 Latest Developments Related to the Pipeline Products
- 4.23.2.1.1 Product: Recent Developments
- 4.23.3 Adamis Pharmaceuticals Corporation. -Asthma & COPD Market Forecast, 2019-2030
- 4.24 Dimerix – Company Overview & Analysis
- 4.24.1 Dimerix Marketed Asthma & COPD Products
- 4.24.2 Dimerix: Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.24.2.1 Latest Developments Related to The Pipeline Products
- 4.24.2.1.1 Product: Recent Developments
- 4.24.3 Dimerix -Asthma & COPD Market Forecast, 2019-2030
- 4.25 Innoviva– Company Overview & Analysis
- 4.25.1 Innoviva. Marketed Asthma & COPD Products
- 4.25.1.1 Product: Recent Developments
- 4.25.2 Innoviva. -Asthma & COPD Market Forecast, 2019-2030
- 4.26 Mereo Biopharma Group Plc– Company Overview & Analysis
- 4.26.1 Mereo Biopharma Group Plc Marketed Asthma & COPD Products
- 4.26.2 Mereo Biopharma Group Plc: Asthma & COPD Products- R&D Pipeline & Future Outlook
- 4.26.2.1 Latest Developments Related to the Pipeline Products
- 4.26.2.1.1 Product: Recent Developments
- 4.26.3 Mereo Biopharma Group Plc -Asthma & COPD Market Forecast, 2019-2030
- 5 Conclusions
- 5.1 Asthma & COPD Products: A Maturing Market
- 5.2 The Global Asthma & COPD Companies Market In 2020-2030
- 5.3 Leading Asthma & COPD Companies
- 5.4 Global Asthma & COPD Products Market Forecast 2020-2030
- 5.5 The Future of the Asthma & COPD Products Market
- 5.5.1 Growth in Anti-Inflammatory and Combination Drugs
- 5.5.2 Personalised Medicine
- 5.5.3 Unmet needs in Asthma and COPD
- 5.6 Strategies for Growth in 2020-2030
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain Report Evaluation Form
- List of Tables
- Table 2.1 Advantages and Disadvantages of The Main Types of Asthma Inhalers
- Table 2.2 E-Technology Based Inhalers
- Table 3.1 Global Market Forecast: Revenues ($Bn), AGR (%) By Leading Companies, 2019-2030
- Table 3.2 Leading Companies in Asthma & COPD Diseases
- Table 3.3 Leading Asthma & COPD Companies: Revenues ($Bn) And Market Shares (%), 2019 And 2030
- Table 4.1 Astrazeneca: Company Overview
- Table 4.2 Astrazeneca: Products Portfolio
- Table 4.3 Astrazeneca: Products Pipeline Portfolio
- Table 4.4 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.5 Glaxosmithkline: Company Overview
- Table 4.6 Glaxosmithkline: Products Portfolio
- Table 4.7 Glaxosmithkline: Products Pipeline Portfolio
- Table 4.8 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.9 Boehringer Ingelheim: Company Overview
- Table 4.10 Boehringer Ingelheim: Products Portfolio
- Table 4.11 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.12 Teva: Company Overview
- Table 4.13 Teva: Products Portfolio
- Table 4.14 Teva: Products Pipeline Portfolio
- Table 4.15 Teva: Asthma & COPD Products Forecast: Revenue ($Bn), AGR(%), CAGR (%), 2019-2030
- Table 4.16 Merck: Company Overview
- Table 4.17 Merck: Products Portfolio
- Table 4.18 Merck: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.19 Roche: Company Overview
- Table 4.20 Roche: Products Portfolio
- Table 4.21 Roche: Products Pipeline Portfolio
- Table 4.22 Roche: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.23 Novartis: Company Overview
- Table 4.24 Novartis: Products Portfolio
- Table 4.25 Novartis: Products Pipeline Portfolio
- Table 4.26 Novartis: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.27 Regeneron Pharmaceuticals (Sanofi): Company Overview
- Table 4.28 Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio
- Table 4.29 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.30 Mundipharma: Company Overview
- Table 4.31 Mundipharma: Products Portfolio
- Table 4.32 Mundipharma: Products Pipeline Portfolio
- Table 4.33 Theravance Biopharma: Company Overview
- Table 4.34 Theravance Biopharma: Products Portfolio
- Table 4.35 Theravance Biopharma: Products Pipeline Portfolio
- Table 4.36 Amphastar Pharmaceuticals: Company Overview
- Table 4.37 Amphastar Pharmaceuticals: Products Pipeline Portfolio
- Table 4.38 Cipla: Company Overview
- Table 4.39 Cipla: Products Portfolio
- Table 4.40 Sunovion Pharmaceuticals: Company Overview
- Table 4.41 Sunovion Pharmaceuticals: Products Portfolio
- Table 4.42 Sunovion: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
- Table 4.43 Circassia: Company Overview
- Table 4.44 Circassia: Products Portfolio
- Table 4.45 Circassia: Products Pipeline Portfolio
- Table 4.46 Vectura Group: Company Overview
- Table 4.47 Vectura Group: Products Portfolio
- Table 4.48 Vectura Group: Products Pipeline Portfolio
- Table 4.49 Lallemand Pharma Ag: Company Overview
- Table 4.50 Lallemand Pharma Ag: Products Portfolio
- Table 4.51 Lallemand Pharma Ag: Products Pipeline Portfolio
- Table 4.52 Chiesi Farmaceutici S.P.A: Company Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook